Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Geron (GERN – Research Report). The associated price target was lowered to $5.00.
Tara Bancroft’s rating is based on a combination of factors that highlight both challenges and opportunities for Geron. Despite a slight beat in Q4 Rytelo sales, there is a noted concern about the flattening of sales due to the majority of new patient starts coming from later lines of treatment. This indicates a need for Geron to focus on increasing uptake from earlier lines, particularly the ESA-relapsing, non-RS 2L population, which presents a significant opportunity for growth given the unmet needs in this segment.
To address these challenges and capitalize on opportunities, Geron is enhancing its regional outreach efforts. The company plans to utilize its sales force and medical affairs team to improve physician engagement and education, aiming to ensure consistent performance across all target accounts. This strategic focus on regional engagement, coupled with the clinical benefits of Rytelo, supports the positive outlook and the Buy rating given by Tara Bancroft.
According to TipRanks, Bancroft is an analyst with an average return of -8.7% and a 22.83% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Merus, and Protagonist Therapeutics.
In another report released on February 18, B.Riley Financial also maintained a Buy rating on the stock with a $3.50 price target.